Neurocrine Biosciences

Neurocrine hands back 2 CNS gene therapy programs to Voyager

Neurocrine handed back two discovery-stage gene therapy programs to Voyager, although the companies’ wider CNS-focused collaboration remains on track.

James Waldron May 7, 2025 7:30am

J&J innovator vaults to Valo—Chutes & Ladders

Apr 11, 2025 8:30am

Three blocks displaying from left to right a person a handshake and another person

Harbour spinoff pens $395M deal for preclinical Crenessity rival

Feb 26, 2025 5:14am

Takeda taps Julie Kim as new CEO—Chutes & Ladders

Jan 31, 2025 8:30am

A puzzle of the brain with one missing piece

Takeda regains home rights to depression drug from Neurocrine

Jan 28, 2025 4:16am

Neurocrine, Idorsia part ways 2 years after double phase 2 fails

Oct 29, 2024 7:15am